Show Summary Details

Page of

PRINTED FROM OXFORD HANDBOOKS ONLINE (www.oxfordhandbooks.com). © Oxford University Press, 2018. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Handbooks Online for personal use (for details see Privacy Policy and Legal Notice).

date: 19 June 2019

Abstract and Keywords

This chapter informs school psychologists about recent growth in the use of psychotropic drugs with children and adolescents, and related controversies (e.g., polypharmacy, off-label prescribing, drug industry marketing practices, and publication biases). It describes a potential role as “knowledge brokers” for school psychologists with appropriate competencies to assist decision-makers in selecting drug, psychosocial, or combination treatments. The chapter reviews safety concerns, including U.S. Food and Drug Administration (FDA) warnings and advisories, and common drug side effects and interaction effects. It reviews efficacy evidence, including FDA drug indications and approvals, randomized controlled clinical trials (RCTs) and meta-analyses of RCTs. The chapter identifies several future research directions which school psychologists may be uniquely qualified to pursue.

Keywords: pediatric psychotropics, school psychology, safety, efficacy, controversies, future research, knowledge broker, disorders, polypharmacy, FDA warnings, FDA indications

Access to the complete content on Oxford Handbooks Online requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can''t find the answer there, please contact us.